Citi left its Boston Scientific BSX price target of $6.70 unchanged prior to its conference call with the company this morning, as stated in a research report published today.
In the report, Citi states, "4Q10 EPS missed Street views when a $0.05 tax variance and lower R&D spend are factored in. Weak 2011 guidance means more trouble lies ahead in both pricing and volume trends and we expect another round of downward estimate revisions today."
Shares of Boston Scientific were at $6.90 at the time of posting in pre-market trading, down 3.23% from Tuesday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in